Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$-0.20
EPS est.
$-0.20
EPS surprise
+0.00%
1-day move
-3.54%
Cryoport's earnings report shows a solid revenue growth of 15% year-over-year, particularly in Life Sciences Services. However, the stock fell by 3.54%, likely due to the slight miss on EPS expectations. The company's reaffirmation of revenue guidance suggests confidence in their growth trajectory despite macroeconomic challenges.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.20 | $-0.18 | +0.00% |
| Revenue | $49M | $48M | N/A |
| Adjusted EBITDA | $400,000 | N/A | N/A |
| Life Sciences Services Revenue Growth | 15% | N/A | N/A |
| BioStorage BioServices Revenue Growth | 25% | N/A | N/A |
Management expressed cautious optimism about future growth, highlighting a strong performance in Life Sciences Services. They reaffirmed their revenue guidance for the fiscal year despite market uncertainties.
CryoPort reaffirmed its FY26 revenue guidance amid macroeconomic uncertainties.
The number of clinical trials supported increased to 779.
Cryoport, Inc. is a healthcare company specializing in life sciences tools and services, particularly in temperature-controlled logistics for biopharmaceutical products. With a market cap of $1 billion, it plays a crucial role in the growing demand for advanced healthcare solutions, especially in the context of personalized medicine and cell and gene therapies.
Last quarter
In Q1-2026, Cryoport reported an EPS of $-0.25, missing expectations by a significant margin. The stock reacted negatively, declining by 1.35% the following day.
EPS beat streak
0Q
EPS beat rate
38%
Avg EPS surprise
+141.73%
Avg 1-day reaction
+0.29%
Analysts expect Cryoport to report a loss of $-0.18 per share on revenues of $48 million for Q2-2026. The company has faced challenges in meeting earnings expectations in recent quarters.
Bull case
If Cryoport can exceed the EPS estimate and show strong revenue growth, it may signal a turnaround in its financial performance, boosting investor confidence.
Bear case
Conversely, if the company fails to meet earnings expectations again, it could lead to further declines in stock price and investor sentiment.
Key metrics to watch
EPS
$-0.18Earnings per share (EPS) is a key indicator of the company's profitability and financial health.
Revenue
$48MRevenue figures provide insight into the company's sales performance and market demand for its services.
The print will turn on these.
Q1
Will Cryoport's revenue reach or exceed the consensus estimate of $48 million?
Revenue performance is crucial for assessing the company's growth trajectory and market demand for its services.
Q2
How will management address the recent trend of missing EPS estimates?
Investors will be keen to hear management's strategy for improving profitability and restoring confidence in the company's financial outlook.
—
Est. EPS
$1.48
Est. Rev
$3.3B
Impl. Move
±16.9%
Why consensus could be wrong
The Street may underestimate the potential for Cryoport to leverage new partnerships and expand its service offerings, which could drive revenue growth.
Supporting evidence
Recent trends in biopharmaceutical logistics indicate increasing demand for temperature-controlled services.
The options market is pricing in a significant move, suggesting that investors are anticipating a major shift in sentiment.
Key risk
If revenue comes in significantly above $48 million, it could challenge the current bearish outlook.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around whether Cryoport can turn around its recent performance and meet or exceed market expectations.
Bull confirmed if
Achieving an EPS better than $-0.18 and revenue growth above $48 million would confirm the bull case.
Bear confirmed if
An EPS worse than $-0.20 or revenue falling below $47 million would confirm the bear case.
What the market is pricing for the move.
Implied Move
±25.97%
Historical Avg
±3.0%
The options market is pricing in a significant potential move in either direction, indicating heightened uncertainty around the earnings report.
Options are pricing ±26.0% while CYRX has averaged ±3.0% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
69.4%
Smart-money positioning from the most recent 13F filings.
Institutional
95.25%
of float
Insider
3.86%
of float
Holders
247
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
4,218,434 sh · $73.2M
8.33%
6.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Cryoport beats expectations, history suggests a potential stock increase of around 2.78%, confirming a positive turnaround narrative.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.
Miss
If the company misses expectations, history suggests a potential decline of around 2.78%, which could further dampen investor sentiment.
The lines on the call that would change the story.
Cadian Capital Management, LP
2,920,681 sh · $50.7M
5.77%
-38.8%
Morgan Stanley
2,276,741 sh · $39.5M
4.50%
-50.2%
Vanguard Capital Management LLC
2,151,943 sh · $37.3M
4.25%
1.6%
Millennium Management Llc
1,724,726 sh · $29.9M
3.41%
-41.9%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.